In this episode, Ian revisits the notion of number needed to treat (NNT) and absolute risk ratio (ARR) from a few episodes ago, in light of some new claims made about mAb therapies for the treatment of COVID-19 patients, given some of the public support for their early use. As always, the approach taken is a methodological one, and the focus is not on COVID-19 per se.
